4Wealth Advisors’s ACELYRIN SLRN Stock Holding History

4Wealth Advisors’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-11,212	Closed	-$35.2K	–	142
2024 Q4	$35.2K	Buy	+11,212	New	+$54.3K	0.04%	143

Other funds holding SLRN

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

ACMC

AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

4Wealth Advisors's SLRN Position: Q1 2025 in Review

4Wealth Advisors sold out of ACELYRIN (SLRN) in Q1 2025, closing a stake of 11,212 shares — an estimated $35.2K sold.

4Wealth Advisors first reported a position in SLRN in Q4 2024 and held it in 1 quarter. The position peaked at $35.2K in Q4 2024. 105 funds tracked by Wall St. Rank hold SLRN as of Q1 2025.

4Wealth Advisors reported no remaining ACELYRIN position as of Q1 2025 after selling out during the quarter.
4Wealth Advisors sold 11,212 ACELYRIN shares in Q1 2025, an estimated $35.2K.
4Wealth Advisors first reported a position in ACELYRIN in Q4 2024 and held it in 1 quarter.
4Wealth Advisors's ACELYRIN position peaked at $35.2K in Q4 2024.
105 funds tracked by Wall St. Rank held ACELYRIN as of Q1 2025.

Based on 4Wealth Advisors's 13F filing for Q1 2025, filed 5 May 2025.